The use of hybrid virus-like particles to enhance the immunogenicity of a broadly protective HPV vaccine.
about
BALB/c mice immunized with a combination of virus-like particles incorporating Kaposi sarcoma-associated herpesvirus (KSHV) envelope glycoproteins gpK8.1, gB, and gH/gL induced comparable serum neutralizing antibody activity to UV-inactivated KSHV.Chimeric rabies virus-like particles containing membrane-anchored GM-CSF enhances the immune response against rabies virus.Preclinical refinements of a broadly protective VLP-based HPV vaccine targeting the minor capsid protein, L2A human monoclonal antibody against HPV16 recognizes an immunodominant and neutralizing epitope partially overlapping with that of H16.V5Novel miR-122 delivery system based on MS2 virus like particle surface displaying cell-penetrating peptide TAT for hepatocellular carcinoma.Small Wonders-The Use of Nanoparticles for Delivering Antigen.Prophylactic HPV vaccination: past, present, and future.The application of virus-like particles as vaccines and biological vehicles.Functional assessment and structural basis of antibody binding to human papillomavirus capsid.Virus-based nanoparticles as platform technologies for modern vaccines.Design of nanomaterial based systems for novel vaccine development.Marburg virus-like particles by co-expression of glycoprotein and matrix protein in insect cells induces immune responses in miceNanoparticle Vaccines Against Infectious Diseases
P2860
Q33798426-6E45356D-5945-4A90-AD2F-AF16D801FACAQ35232804-BE8C92DC-C2E3-445F-ABBB-46D2741982A2Q35744303-E63FDC74-4B96-45C5-9AA5-6011AB63AB3FQ36448778-CEFF130F-8984-4190-88BE-F69B0B412F47Q37644875-BDE5BEDE-CC84-4E01-97C0-2214B2097726Q38583148-76DC0AAA-2A15-42A5-88B2-990FC51B86E0Q38597567-651AB262-A0B4-421D-93B1-A821AFC0076DQ38603912-A721A613-0711-402F-8FE5-994E592CE951Q38671633-D0DE9042-1DE0-4202-838C-B51C9D7146CEQ38702017-89C63DB6-6A57-4E71-A593-4DBA6B9E0394Q38739675-0C211E58-A089-4575-A15A-601CF2B02C72Q42628113-03EED39B-F6AA-4F45-BA6B-113D0133F397Q58583890-6D9B2400-22BB-4A17-9662-0AC659989A75
P2860
The use of hybrid virus-like particles to enhance the immunogenicity of a broadly protective HPV vaccine.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
The use of hybrid virus-like p ...... roadly protective HPV vaccine.
@ast
The use of hybrid virus-like p ...... roadly protective HPV vaccine.
@en
type
label
The use of hybrid virus-like p ...... roadly protective HPV vaccine.
@ast
The use of hybrid virus-like p ...... roadly protective HPV vaccine.
@en
prefLabel
The use of hybrid virus-like p ...... roadly protective HPV vaccine.
@ast
The use of hybrid virus-like p ...... roadly protective HPV vaccine.
@en
P2093
P2860
P356
P1476
The use of hybrid virus-like p ...... roadly protective HPV vaccine.
@en
P2093
Bryce Chackerian
David S Peabody
Ebenezer Tumban
Mitchell Tyler
P2860
P304
P356
10.1002/BIT.25311
P577
2014-07-31T00:00:00Z